INVOKANA® (canagliflozin) Official Website HCP

FIRST

In adults with DKD* and T2D, INVOKANA®: the first SGLT2i indicated to reduce the risk of ^6,7:

Pink icon with kidney graphic inside.

ESKD^†
Doubling of serum creatinine
CV death
Hospitalization for heart failure

See data

ONLY

In adults with T2D and established CVD, INVOKANA®: the only SGLT2i indicated to reduce the risk of ⁵:

Purple heart icon with lightning bolt inside.

Purple brain icon.

Purple heart icon with heartbeat graphic inside.

All components of 3-point MACE:
- Heart attack
- Stroke
- CV death

See data

*With albuminuria >300 mg/day.
^†End-stage kidney disease was defined as dialysis for ≥30 days, kidney transplantation, or an eGFR <15 mL/min/1.73 m² sustained for ≥30 days.
CV=cardiovascular; CVD=cardiovascular disease; DKD=diabetic kidney disease; ESKD=end-stage kidney disease; MACE=major adverse cardiovascular events; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.

References: 1. INVOKANA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer lngelheim Pharmaceuticals, Inc. 3. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 4. Steglatro® [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. 5. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. 6. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):‍‍2295-2306. 7. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140(9):739-750.

No footer content content fetched

No footer links content fetched